US FDA declines to approve Outlook Therapeutics' eye disease drug

Reuters

01/01

US FDA declines to approve Outlook <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' eye disease drug

Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market.

(Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Shreya Biswas and Shilpi Majumdar)

((Sriparna.Roy@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2600701342"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2600701342\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2600701342?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-01 05:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600701342","market":"nz","top_or_hot":-1,"title":"US FDA declines to approve Outlook Therapeutics' eye disease drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>US FDA declines to approve Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' eye disease drug</title></head><body><p><span>Dec 31 (Reuters)</span><span> - </span>The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market.</p><p> (Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Shreya Biswas and Shilpi Majumdar)</p><p> ((Sriparna.Roy@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US FDA declines to approve Outlook Therapeutics' eye disease drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS FDA declines to approve Outlook Therapeutics' eye disease drug\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-01-01 05:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>US FDA declines to approve Outlook <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' eye disease drug</title></head><body><p><span>Dec 31 (Reuters)</span><span> - </span>The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market.</p><p> (Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Shreya Biswas and Shilpi Majumdar)</p><p> ((Sriparna.Roy@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nL4N3Y10VF:1","article_id":"2600701342","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600701342","pubTimestamp":1767215956,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"US FDA declines to approve Outlook Therapeutics' eye disease drugDec 31  - The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OTLK":"Outlook Therapeutics, Inc."},"translate_title":"美国FDA拒绝批准Outlook Therapeutics眼病药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OTLK":0.9},"content_text":"US FDA declines to approve Outlook Therapeutics' eye disease drugDec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' drug for a type of eye disease, the company said on Wednesday, marking another setback to its prolonged effort to bring the treatment to market. (Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Shreya Biswas and Shilpi Majumdar) ((Sriparna.Roy@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}